News | January 22, 2014

BioVentrix takes treatment to second European location

Implant of Revivent-TC Ventricular Enhancement System done in Czech Republic

BioVentrix Revivent-TC Heart Failure Treatment Cath Lab Structural Heart

January 22, 2014 — BioVentrix’s Revivent-TC Ventricular Enhancement System was implanted in a man via Less Invasive Ventricular Enhancement (LIVE) in Prague, Czech Republic. 
 
The procedure, which is used to reshape and reduce the left ventricle, was performed on a 64-year-old man suffering from ischemic heart failure.  Prof. Petr Neuzil and Dr. Ivo Skalsky performed the transcatheter procedure at Na Holmoce Hospital without opening the patient’s chest or using a heart-lung bypass machine.
 
“The Revivent-TC hybrid system allows treatment of both worsening heart failure patients, and those who are already very ill, without opening the chest,” said Neuzil, head of cardiology and director of the cardiac arrhythmia service. “This is a major breakthrough for this patient population that will lower the barrier to intervention for all heart failure classifications.”
 
Within three days of the LIVE procedure, the patient’s ejection fraction improved 45 percent improvement, rising from a 31 percent preoperative measurement.
 
For more information: www.bioventrix.com

Related Content

News | Cath Lab

May 13, 2026 — According to a recently released report, the global cath lab services market was valued at $46.0 billion ...

Home May 13, 2026
Home
News | Cath Lab

April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that ...

Home April 20, 2026
Home
News | Cath Lab

April 6, 2026 —Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its Synchrony system ...

Home April 07, 2026
Home
News | Cath Lab

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The ...

Home April 03, 2026
Home
News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
Subscribe Now